Cell type-associated traits map for the [MacParland_2018_liver_Stellate cell][link to cell ontology]. Due to the large number of UKBB panel traits, this figure shows the non-UKBB traits with a CSEA p (chi2) < 1e-04 as default, and users can change it to 1e-03, 1e-05, or 1e-06. For each cell type and trait association pair (shown as an edge in the figure), there may be multiple TAG sets, each defined at a different threshold. The pair with the minimum p-value is shown in the figure, with the p-value showing along each edge. The number of edges in the figure is thus less than (or equal to) the number of entries in the table below.” The association association is listed in the table at bottom, Because each trait might have multiple TAG sets defined at different thresholds, multiple rows for each cell type and trait pair with different "TAG Set Threshold" and " CSEA p (chi2)" (the last two columns).
Table. List of Cell type-associated traits pairs for [MacParland_2018_liver_Stellate cell]. If the network above is too complicated. the users could obtain the association information from the table at bottom. Because each trait has multiple TAG sets defined at different thresholds, there may be multiple rows for each cell type and trait pair with different "TAG Set Threshold" and " CSEA p (chi2)" (the last two columns). Users could identify the most significant association by sorting “CSAE p (chi2)” column.
Trait Name | Trait Full Name | Panel | Author | Year | Cases* | Controls | TAG Set Threshold |
CSEA p (chi2) |
---|---|---|---|---|---|---|---|---|
ADHD | Attention Deficit Hyperactivity Disorder | MTC | Middeldorp | 2016 | NA | 17666 | 5.00e-2 | 4.02e-2 |
Alzheimers | Alzheimer's Disease | ETC | Lambert | 2013 | 17008 | 37154 | 1.00e-5 | 4.07e-2 |
Asthma | Asthma | MTC | Demenais | 2017 | 19954 | 107715 | 1.00e-5 | 2.32e-2 |
Asthma | Asthma | MTC | Moffatt | 2010 | 10365 | 16110 | 1.00e-3 | 2.66e-3 |
Asthma | Asthma | MTC | Moffatt | 2010 | 10365 | 16110 | 1.00e-4 | 4.35e-3 |
Asthma | Asthma | MTC | Moffatt | 2010 | 10365 | 16110 | 1.00e-5 | 1.78e-3 |
Blood Pressure | Blood Pressure | MTC | Ehret | 2011 | NA | 69395 | 5.00e-2 | 1.36e-2 |
Blood Pressure | Blood Pressure | MTC | Ehret | 2011 | NA | 69395 | 1.00e-2 | 2.72e-3 |
Bone Mineral Density Estimated | Bone Mineral Density Estimated | MTC | Kemp | 2017 | NA | 142487 | 1.00e-3 | 9.57e-4 |
Bone Mineral Density Estimated | Bone Mineral Density Estimated | MTC | Kemp | 2017 | NA | 142487 | 1.00e-4 | 2.53e-2 |
CAD | Coronary Artery Disease | MTC | Nelson | 2017 | 18467 | 45264 | 5.00e-2 | 1.87e-3 |
CAD | Coronary Artery Disease | MTC | Nelson | 2017 | 18467 | 45264 | 1.00e-2 | 1.53e-3 |
CAD | Coronary Artery Disease | MTC | Nelson | 2017 | 18467 | 45264 | 1.00e-3 | 1.31e-2 |
CAD | Coronary Artery Disease | MTC | Schunkert | 2011 | 22233 | 64762 | 5.00e-2 | 4.05e-3 |
CAD | Coronary Artery Disease | MTC | Schunkert | 2011 | 22233 | 64762 | 1.00e-3 | 3.07e-2 |
Gout | Gout | MTC | Kottgen | 2013 | 2115 | 67259 | 5.00e-2 | 4.54e-2 |
Height | Height | MTC | Lango-Allen | 2010 | NA | 133653 | 5.00e-2 | 1.75e-4 |
Height | Height | MTC | Lango-Allen | 2010 | NA | 133653 | 1.00e-2 | 7.21e-4 |
Height | Height | MTC | Lango-Allen | 2010 | NA | 133653 | 1.00e-3 | 5.77e-4 |
Height | Height | MTC | Lango-Allen | 2010 | NA | 133653 | 1.00e-4 | 1.64e-2 |
Height | Height | MTC | Lango-Allen | 2010 | NA | 133653 | 1.00e-5 | 4.77e-2 |
MDD | Major Depressive Disorder | MTC | PGC | 2013 | 9240 | 9519 | 5.00e-2 | 1.04e-2 |
MDD | Major Depressive Disorder | MTC | PGC | 2013 | 9240 | 9519 | 1.00e-2 | 2.78e-3 |
MDD | Major Depressive Disorder | MTC | PGC | 2013 | 9240 | 9519 | 1.00e-3 | 1.28e-2 |
Male Pattern Baldness | Male Pattern Baldness | MTC | Hagenaars | 2017 | NA | 52874 | 1.00e-2 | 3.89e-3 |
Male Pattern Baldness | Male Pattern Baldness | MTC | Hagenaars | 2017 | NA | 52874 | 1.00e-3 | 3.41e-2 |
Male Pattern Baldness | Male Pattern Baldness | MTC | Hagenaars | 2017 | NA | 52874 | 1.00e-4 | 2.04e-2 |
Male Pattern Baldness | Male Pattern Baldness | MTC | Hagenaars | 2017 | NA | 52874 | 1.00e-5 | 2.50e-2 |
Tetralogy Of Fallot | Tetralogy Of Fallot | MTC | Cordell | 2013 | 835 | 5159 | 5.00e-2 | 5.96e-3 |
Tetralogy Of Fallot | Tetralogy Of Fallot | MTC | Cordell | 2013 | 835 | 5159 | 1.00e-2 | 2.15e-3 |
UC | Ulcerative Colitis | MTC | Anderson | 2011 | 6687 | 19718 | 5.00e-2 | 4.89e-2 |
Albuminuria | Microalbuminuria | MTC | Boger | 2011 | NA | 31580 | 5.00e-2 | 1.82e-2 |
Albuminuria | Microalbuminuria | MTC | Teumer | 2016 | NA | 54116 | 5.00e-2 | 8.71e-4 |
Albuminuria | Urinary Albumin to Creatinine Ratio | MTC | Teumer | 2016 | NA | 54450 | 1.00e-3 | 2.29e-2 |
Albuminuria | Urinary Albumin to Creatinine Ratio In Nondiabetics | MTC | Teumer | 2016 | NA | 46051 | 1.00e-3 | 2.94e-2 |
Alcohol Consumption | Alcohol Consumption All Continuous | MTC | Schumann | 2016 | NA | 70460 | 1.00e-2 | 2.18e-2 |
Alcohol Consumption | Alcohol Consumption All Dichotomous | MTC | Schumann | 2016 | NA | 74711 | 5.00e-2 | 1.31e-2 |
Anthropometric Extremes | Extreme Height | MTC | Berndt | 2013 | 8097 | 8099 | 5.00e-2 | 3.00e-4 |
Anthropometric Extremes | Extreme Height | MTC | Berndt | 2013 | 8097 | 8099 | 1.00e-2 | 1.76e-3 |
Anthropometric Extremes | Extreme Height | MTC | Berndt | 2013 | 8097 | 8099 | 1.00e-3 | 3.01e-3 |
Anthropometric Extremes | Extreme Height | MTC | Berndt | 2013 | 8097 | 8099 | 1.00e-4 | 5.03e-3 |
Anthropometric Extremes | Extreme Height | MTC | Berndt | 2013 | 8097 | 8099 | 1.00e-5 | 2.78e-2 |
Anthropometrics Sex Stratified | Height Men | MTC | Randall | 2013 | NA | 60856 | 5.00e-2 | 1.12e-2 |
Anthropometrics Sex Stratified | Height Men | MTC | Randall | 2013 | NA | 60856 | 1.00e-2 | 1.56e-2 |
Anthropometrics Sex Stratified | Height Men | MTC | Randall | 2013 | NA | 60856 | 1.00e-3 | 2.83e-4 |
Anthropometrics Sex Stratified | Height Men | MTC | Randall | 2013 | NA | 60856 | 1.00e-4 | 5.51e-3 |
Anthropometrics Sex Stratified | Height Men | MTC | Randall | 2013 | NA | 60856 | 1.00e-5 | 1.84e-2 |
Anthropometrics Sex Stratified | Height Women | MTC | Randall | 2013 | NA | 73137 | 5.00e-2 | 4.06e-6 |
Anthropometrics Sex Stratified | Height Women | MTC | Randall | 2013 | NA | 73137 | 1.00e-2 | 2.22e-3 |
Anthropometrics Sex Stratified | Hip Circumference Adjusted For BMI Men | MTC | Randall | 2013 | NA | 34942 | 5.00e-2 | 4.17e-2 |
Anthropometrics Sex Stratified | Waist Circumference Adjusted For BMI Men | MTC | Randall | 2013 | NA | 36231 | 1.00e-2 | 1.07e-3 |
Anthropometrics Sex Stratified | Waist Circumference Adjusted For BMI Men | MTC | Randall | 2013 | NA | 36231 | 1.00e-3 | 5.39e-4 |
Anthropometrics Sex Stratified | Waist Hip Ratio Adjusted For BMI Men | MTC | Randall | 2013 | NA | 34629 | 5.00e-2 | 3.88e-2 |
Anxiety | Anxiety Continuous | ETC | Otowa | 2016 | NA | 18186 | 1.00e-2 | 4.71e-2 |
Aortic Valve Calcification | Mitral Annular Calcification | MTC | Thanassoulis | 2013 | NA | 3795 | 1.00e-2 | 2.69e-2 |
Birth Weight | Birth Weight European | ETC | Horikoshi | 2016 | NA | 133903 | 5.00e-2 | 4.16e-2 |
Birth Weight | Birth Weight European | ETC | Horikoshi | 2016 | NA | 133903 | 1.00e-2 | 2.40e-2 |
Blood Cells | Hematocrit | MTC | Ferreira | 2009 | NA | 6015 | 5.00e-2 | 2.10e-2 |
Blood Cells | Total Blood Hemoglobin | MTC | Ferreira | 2009 | NA | 6015 | 5.00e-2 | 1.42e-2 |
BMI Age Stratified | Waist Hip Ratio Adjusted For BMI Men Under 50 | MTC | Winkler | 2015 | NA | 43776 | 5.00e-2 | 3.78e-2 |
BMI Age Stratified | Waist Hip Ratio Adjusted For BMI Women Under 50 | MTC | Winkler | 2015 | NA | 50526 | 5.00e-2 | 4.17e-2 |
BMI Age Stratified | Waist Hip Ratio Adjusted For BMI Women Under 50 | MTC | Winkler | 2015 | NA | 50526 | 1.00e-2 | 4.01e-2 |
BMI Physical Activity Interaction | Waist Circumference Adjusted For BMI Active European | MTC | GIANT | 2017 | NA | 234069 | 5.00e-2 | 2.74e-4 |
BMI Physical Activity Interaction | Waist Circumference Adjusted For BMI Active European | MTC | GIANT | 2017 | NA | 234069 | 1.00e-2 | 2.20e-3 |
BMI Physical Activity Interaction | Waist Circumference Adjusted For BMI Active European | MTC | GIANT | 2017 | NA | 234069 | 1.00e-3 | 7.29e-3 |
BMI Physical Activity Interaction | Waist Circumference Adjusted For BMI Active European | MTC | GIANT | 2017 | NA | 234069 | 1.00e-4 | 4.12e-4 |
BMI Physical Activity Interaction | Waist Circumference Adjusted For BMI Active European | MTC | GIANT | 2017 | NA | 234069 | 1.00e-5 | 2.86e-5 |
BMI Physical Activity Interaction | Waist Circumference Adjusted For BMI Active European Men | MTC | GIANT | 2017 | NA | 104666 | 5.00e-2 | 1.55e-2 |
BMI Physical Activity Interaction | Waist Circumference Adjusted For BMI Active European Men | MTC | GIANT | 2017 | NA | 104666 | 1.00e-2 | 1.51e-4 |
BMI Physical Activity Interaction | Waist Circumference Adjusted For BMI Active European Men | MTC | GIANT | 2017 | NA | 104666 | 1.00e-3 | 4.97e-4 |
BMI Physical Activity Interaction | Waist Circumference Adjusted For BMI Active European Men | MTC | GIANT | 2017 | NA | 104666 | 1.00e-4 | 1.50e-3 |
BMI Physical Activity Interaction | Waist Circumference Adjusted For BMI Active European Women | MTC | GIANT | 2017 | NA | 132115 | 1.00e-2 | 2.87e-2 |
BMI Physical Activity Interaction | Waist Circumference Adjusted For BMI Active European Women | MTC | GIANT | 2017 | NA | 132115 | 1.00e-3 | 2.97e-2 |
BMI Physical Activity Interaction | Waist Circumference Adjusted For BMI Adjusted For Physical Activity European | MTC | GIANT | 2017 | NA | 234069 | 5.00e-2 | 6.95e-3 |
BMI Physical Activity Interaction | Waist Circumference Adjusted For BMI Adjusted For Physical Activity European | MTC | GIANT | 2017 | NA | 234069 | 1.00e-2 | 1.58e-3 |
BMI Physical Activity Interaction | Waist Circumference Adjusted For BMI Adjusted For Physical Activity European | MTC | GIANT | 2017 | NA | 234069 | 1.00e-4 | 4.45e-3 |
BMI Physical Activity Interaction | Waist Circumference Adjusted For BMI Adjusted For Physical Activity European | MTC | GIANT | 2017 | NA | 234069 | 1.00e-5 | 3.62e-3 |
BMI Physical Activity Interaction | Waist Circumference Adjusted For BMI Adjusted For Physical Activity European Men | MTC | GIANT | 2017 | NA | 104666 | 5.00e-2 | 9.18e-5 |
BMI Physical Activity Interaction | Waist Circumference Adjusted For BMI Adjusted For Physical Activity European Men | MTC | GIANT | 2017 | NA | 104666 | 1.00e-2 | 6.16e-5 |
BMI Physical Activity Interaction | Waist Circumference Adjusted For BMI Adjusted For Physical Activity European Men | MTC | GIANT | 2017 | NA | 104666 | 1.00e-3 | 1.69e-3 |
BMI Physical Activity Interaction | Waist Circumference Adjusted For BMI Adjusted For Physical Activity European Men | MTC | GIANT | 2017 | NA | 104666 | 1.00e-4 | 1.08e-2 |
BMI Physical Activity Interaction | Waist Circumference Adjusted For BMI Adjusted For Physical Activity European Women | MTC | GIANT | 2017 | NA | 132115 | 1.00e-3 | 2.50e-2 |
BMI Physical Activity Interaction | Waist Circumference Adjusted For BMI Inactive European Men | MTC | GIANT | 2017 | NA | 104666 | 1.00e-2 | 3.11e-2 |
BMI Physical Activity Interaction | Waist Hip Ratio Adjusted For BMI Active European | MTC | GIANT | 2017 | NA | 234069 | 5.00e-2 | 3.58e-3 |
BMI Physical Activity Interaction | Waist Hip Ratio Adjusted For BMI Active European Men | MTC | GIANT | 2017 | NA | 104666 | 5.00e-2 | 3.58e-2 |
BMI Physical Activity Interaction | Waist Hip Ratio Adjusted For BMI Adjusted For Physical Activity European | MTC | GIANT | 2017 | NA | 234069 | 5.00e-2 | 1.37e-3 |
BMI Physical Activity Interaction | Waist Hip Ratio Adjusted For BMI Adjusted For Physical Activity European Men | MTC | GIANT | 2017 | NA | 104666 | 1.00e-3 | 3.10e-2 |
BMI Physical Activity Interaction | Waist Hip Ratio Adjusted For BMI Adjusted For Physical Activity European Women | MTC | GIANT | 2017 | NA | 132115 | 1.00e-2 | 4.29e-2 |
BMI Smoking Adjusted | Waist Circumference Adjusted BMI Adjusted Smoking European | MTC | GIANT | 2017 | NA | 234069 | 5.00e-2 | 1.15e-3 |
BMI Smoking Adjusted | Waist Circumference Adjusted BMI Adjusted Smoking European | MTC | GIANT | 2017 | NA | 234069 | 1.00e-2 | 6.12e-5 |
BMI Smoking Adjusted | Waist Circumference Adjusted BMI Adjusted Smoking European | MTC | GIANT | 2017 | NA | 234069 | 1.00e-3 | 1.91e-3 |
BMI Smoking Adjusted | Waist Circumference Adjusted BMI Adjusted Smoking European | MTC | GIANT | 2017 | NA | 234069 | 1.00e-4 | 1.21e-2 |
BMI Smoking Adjusted | Waist Circumference Adjusted BMI Adjusted Smoking European | MTC | GIANT | 2017 | NA | 234069 | 1.00e-5 | 3.11e-4 |
BMI Smoking Adjusted | Waist Circumference Adjusted BMI Adjusted Smoking Men European | MTC | GIANT | 2017 | NA | 104666 | 5.00e-2 | 5.76e-5 |
BMI Smoking Adjusted | Waist Circumference Adjusted BMI Adjusted Smoking Men European | MTC | GIANT | 2017 | NA | 104666 | 1.00e-2 | 1.08e-5 |
BMI Smoking Adjusted | Waist Circumference Adjusted BMI Adjusted Smoking Men European | MTC | GIANT | 2017 | NA | 104666 | 1.00e-3 | 3.97e-4 |
BMI Smoking Adjusted | Waist Circumference Adjusted BMI Adjusted Smoking Men European | MTC | GIANT | 2017 | NA | 104666 | 1.00e-4 | 2.10e-2 |
BMI Smoking Adjusted | Waist Circumference Adjusted BMI Adjusted Smoking Men European | MTC | GIANT | 2017 | NA | 104666 | 1.00e-5 | 3.57e-2 |
BMI Smoking Adjusted | Waist Circumference Adjusted BMI Adjusted Smoking Women European | MTC | GIANT | 2017 | NA | 132115 | 5.00e-2 | 2.41e-3 |
BMI Smoking Adjusted | Waist Circumference Adjusted BMI Adjusted Smoking Women European | MTC | GIANT | 2017 | NA | 132115 | 1.00e-2 | 1.15e-3 |
BMI Smoking Adjusted | Waist Circumference Adjusted BMI Adjusted Smoking Women European | MTC | GIANT | 2017 | NA | 132115 | 1.00e-3 | 3.31e-2 |
BMI Smoking Adjusted | Waist Circumference Adjusted BMI Adjusted Smoking Women European | MTC | GIANT | 2017 | NA | 132115 | 1.00e-4 | 2.27e-3 |
BMI Smoking Adjusted | Waist Circumference Adjusted BMI Adjusted Smoking Women European | MTC | GIANT | 2017 | NA | 132115 | 1.00e-5 | 1.14e-2 |
BMI Smoking Adjusted | Waist Hip Ratio Adjusted BMI Adjusted Smoking European | MTC | GIANT | 2017 | NA | 234069 | 5.00e-2 | 4.29e-4 |
BMI Smoking Adjusted | Waist Hip Ratio Adjusted BMI Adjusted Smoking European | MTC | GIANT | 2017 | NA | 234069 | 1.00e-2 | 1.12e-5 |
BMI Smoking Adjusted | Waist Hip Ratio Adjusted BMI Adjusted Smoking European | MTC | GIANT | 2017 | NA | 234069 | 1.00e-3 | 1.29e-6 |
BMI Smoking Adjusted | Waist Hip Ratio Adjusted BMI Adjusted Smoking European | MTC | GIANT | 2017 | NA | 234069 | 1.00e-4 | 2.99e-5 |
BMI Smoking Adjusted | Waist Hip Ratio Adjusted BMI Adjusted Smoking European | MTC | GIANT | 2017 | NA | 234069 | 1.00e-5 | 1.42e-4 |
BMI Smoking Adjusted | Waist Hip Ratio Adjusted BMI Adjusted Smoking Women European | MTC | GIANT | 2017 | NA | 132115 | 5.00e-2 | 1.70e-3 |
BMI Smoking Adjusted | Waist Hip Ratio Adjusted BMI Adjusted Smoking Women European | MTC | GIANT | 2017 | NA | 132115 | 1.00e-2 | 1.72e-4 |
BMI Smoking Adjusted | Waist Hip Ratio Adjusted BMI Adjusted Smoking Women European | MTC | GIANT | 2017 | NA | 132115 | 1.00e-3 | 1.26e-6 |
BMI Smoking Adjusted | Waist Hip Ratio Adjusted BMI Adjusted Smoking Women European | MTC | GIANT | 2017 | NA | 132115 | 1.00e-4 | 8.66e-4 |
BMI Smoking Adjusted | Waist Hip Ratio Adjusted BMI Adjusted Smoking Women European | MTC | GIANT | 2017 | NA | 132115 | 1.00e-5 | 1.53e-3 |
Bone Mineral Density | Femoral Neck Bone Mineral Density All | MTC | Estrada | 2012 | NA | 32961 | 5.00e-2 | 4.44e-2 |
Bone Mineral Density | Femoral Neck Bone Mineral Density All | MTC | Estrada | 2012 | NA | 32961 | 1.00e-4 | 4.61e-2 |
Bone Mineral Density | Femoral Neck Bone Mineral Density Men | MTC | Estrada | 2012 | NA | 32961 | 1.00e-3 | 3.50e-3 |
Bone Mineral Density | Lumbar Spine Bone Mineral Density All | MTC | Estrada | 2012 | NA | 31800 | 1.00e-2 | 4.71e-3 |
Bone Mineral Density | Lumbar Spine Bone Mineral Density All | MTC | Estrada | 2012 | NA | 31800 | 1.00e-3 | 3.85e-2 |
Bone Mineral Density | Lumbar Spine Bone Mineral Density Women | MTC | Estrada | 2012 | NA | 31800 | 5.00e-2 | 1.24e-2 |
Bone Mineral Density Lifecourse | Total Body Bone Mineral Density 15 to 30 | MTC | Medina-Gomez | 2018 | NA | 4180 | 5.00e-2 | 1.93e-2 |
Bone Mineral Density Lifecourse | Total Body Bone Mineral Density 45 to 60 | MTC | Medina-Gomez | 2018 | NA | 18805 | 5.00e-2 | 2.27e-3 |
Bone Mineral Density Lifecourse | Total Body Bone Mineral Density 45 to 60 | MTC | Medina-Gomez | 2018 | NA | 18805 | 1.00e-2 | 5.38e-3 |
Bone Mineral Density Lifecourse | Total Body Bone Mineral Density 45 to 60 | MTC | Medina-Gomez | 2018 | NA | 18805 | 1.00e-4 | 2.52e-2 |
Bone Mineral Density Lifecourse | Total Body Bone Mineral Density All | MTC | Medina-Gomez | 2018 | NA | 56284 | 1.00e-2 | 3.16e-3 |
Bone Mineral Density Lifecourse | Total Body Bone Mineral Density All | MTC | Medina-Gomez | 2018 | NA | 56284 | 1.00e-3 | 7.59e-4 |
Bone Mineral Density Lifecourse | Total Body Bone Mineral Density All | MTC | Medina-Gomez | 2018 | NA | 56284 | 1.00e-4 | 1.12e-2 |
Bone Mineral Density | Femoral Neck Bone Mineral Density | ETC | Zheng | 2015 | NA | 26320 | 1.00e-2 | 2.87e-2 |
Bone Mineral Density | Lumbar Spine Bone Mineral Density | MTC | Zheng | 2015 | NA | 23699 | 5.00e-2 | 3.20e-3 |
Bone Mineral Density | Lumbar Spine Bone Mineral Density | MTC | Zheng | 2015 | NA | 23699 | 1.00e-2 | 2.38e-2 |
Bone Mineral Density | Lumbar Spine Bone Mineral Density | MTC | Zheng | 2015 | NA | 23699 | 1.00e-5 | 2.37e-2 |
Coronary Artery Disease | Coronary Artery Disease Additive Model | MTC | Nikpay | 2015 | 42096 | 99121 | 5.00e-2 | 7.32e-4 |
Coronary Artery Disease | Coronary Artery Disease Additive Model | MTC | Nikpay | 2015 | 42096 | 99121 | 1.00e-2 | 7.07e-4 |
Coronary Artery Disease | Myocardial Infarction Additive Model | MTC | Nikpay | 2015 | 27509 | 99121 | 5.00e-2 | 4.89e-2 |
Ectopic Fat Traits | Pericardial Adipose Tissue Volume Adjusted For Height Weight All | MTC | Chu | 2017 | NA | 7324 | 1.00e-2 | 3.74e-2 |
Ectopic Fat Traits | Pericardial Adipose Tissue Volume Men | MTC | Chu | 2017 | NA | 3640 | 5.00e-2 | 4.68e-2 |
Ectopic Fat Traits | Ratio Of Visceral To Subcutaneous Adipose Tissue Volume Adjusted For BMI All | MTC | Chu | 2017 | NA | 14668 | 5.00e-2 | 4.75e-3 |
Ectopic Fat Traits | Ratio Of Visceral To Subcutaneous Adipose Tissue Volume Adjusted For BMI All | MTC | Chu | 2017 | NA | 14668 | 1.00e-2 | 5.72e-4 |
Ectopic Fat Traits | Ratio Of Visceral To Subcutaneous Adipose Tissue Volume Adjusted For BMI Women | MTC | Chu | 2017 | NA | 7618 | 5.00e-2 | 9.50e-3 |
Ectopic Fat Traits | Ratio Of Visceral To Subcutaneous Adipose Tissue Volume Adjusted For BMI Women | MTC | Chu | 2017 | NA | 7618 | 1.00e-2 | 1.30e-3 |
Ectopic Fat Traits | Ratio Of Visceral To Subcutaneous Adipose Tissue Volume Adjusted For BMI Women | MTC | Chu | 2017 | NA | 7618 | 1.00e-3 | 7.18e-3 |
Ectopic Fat Traits | Ratio Of Visceral To Subcutaneous Adipose Tissue Volume All | MTC | Chu | 2017 | NA | 14668 | 5.00e-2 | 5.12e-3 |
Ectopic Fat Traits | Ratio Of Visceral To Subcutaneous Adipose Tissue Volume Women | MTC | Chu | 2017 | NA | 7618 | 5.00e-2 | 2.90e-2 |
Ectopic Fat Traits | Ratio Of Visceral To Subcutaneous Adipose Tissue Volume Women | MTC | Chu | 2017 | NA | 7618 | 1.00e-2 | 1.73e-3 |
Ectopic Fat Traits | Visceral Adipose Tissue Attenutation Women | MTC | Chu | 2017 | NA | 5729 | 5.00e-2 | 3.29e-2 |
Ectopic Fat Traits | Visceral Adipose Tissue Attenutation Women | MTC | Chu | 2017 | NA | 5729 | 1.00e-2 | 2.35e-2 |
Ectopic Fat Traits | Visceral Adipose Tissue Volume Adjusted For BMI All | MTC | Chu | 2017 | NA | 14863 | 5.00e-2 | 3.50e-2 |
Ectopic Fat Traits | Visceral Adipose Tissue Volume Adjusted For BMI Women | MTC | Chu | 2017 | NA | 7431 | 1.00e-2 | 4.77e-3 |
Estimated Glomerular Filtration Rate | Serum Creatinine African Americans Only | MTC | Pattaro | 2016 | NA | 133413 | 1.00e-2 | 3.11e-2 |
Facial Shape | Mod12 | MTC | Claes | 2018 | NA | 2329 | 5.00e-2 | 2.06e-2 |
Facial Shape | Mod13 | MTC | Claes | 2018 | NA | 2329 | 5.00e-2 | 5.72e-3 |
Facial Shape | Mod15 | MTC | Claes | 2018 | NA | 2329 | 5.00e-2 | 2.90e-2 |
Facial Shape | Mod18 | MTC | Claes | 2018 | NA | 2329 | 5.00e-2 | 3.75e-2 |
Facial Shape | Mod19 | MTC | Claes | 2018 | NA | 2329 | 5.00e-2 | 2.37e-3 |
Facial Shape | Mod19 | MTC | Claes | 2018 | NA | 2329 | 1.00e-2 | 2.84e-2 |
Facial Shape | Mod19 | MTC | Claes | 2018 | NA | 2329 | 1.00e-3 | 3.40e-2 |
Facial Shape | Mod2 | MTC | Claes | 2018 | NA | 2329 | 5.00e-2 | 2.87e-2 |
Facial Shape | Mod21 | MTC | Claes | 2018 | NA | 2329 | 1.00e-2 | 4.98e-2 |
Facial Shape | Mod26 | MTC | Claes | 2018 | NA | 2329 | 5.00e-2 | 1.54e-2 |
Facial Shape | Mod26 | MTC | Claes | 2018 | NA | 2329 | 1.00e-2 | 1.06e-3 |
Facial Shape | Mod34 | MTC | Claes | 2018 | NA | 2329 | 5.00e-2 | 2.60e-2 |
Facial Shape | Mod36 | MTC | Claes | 2018 | NA | 2329 | 5.00e-2 | 1.51e-2 |
Facial Shape | Mod36 | MTC | Claes | 2018 | NA | 2329 | 1.00e-2 | 8.65e-4 |
Facial Shape | Mod37 | MTC | Claes | 2018 | NA | 2329 | 5.00e-2 | 1.28e-3 |
Facial Shape | Mod39 | MTC | Claes | 2018 | NA | 2329 | 5.00e-2 | 4.50e-2 |
Facial Shape | Mod39 | MTC | Claes | 2018 | NA | 2329 | 1.00e-2 | 3.26e-2 |
Facial Shape | Mod41 | MTC | Claes | 2018 | NA | 2329 | 5.00e-2 | 3.60e-3 |
Facial Shape | Mod52 | MTC | Claes | 2018 | NA | 2329 | 5.00e-2 | 3.10e-2 |
Facial Shape | Mod61 | MTC | Claes | 2018 | NA | 2329 | 5.00e-2 | 2.07e-2 |
Facial Shape | Mod8 | MTC | Claes | 2018 | NA | 2329 | 1.00e-3 | 1.88e-2 |
Facial Shape | Mod9 | MTC | Claes | 2018 | NA | 2329 | 1.00e-3 | 2.29e-2 |
Gestational Weight Gain | Early Gestational Weight Gain Offspring Variants | MTC | Warrington | 2017 | NA | 8559 | 1.00e-2 | 2.76e-3 |
Glycemic Traits | HOMA B | MTC | Dupuis | 2010 | NA | 36466 | 5.00e-2 | 4.02e-2 |
Insulin Secretion | Peak Insulin Response Adjusted For BMI And Insulin Sensitivity | MTC | Wood | 2017 | NA | 2159 | 5.00e-2 | 7.88e-3 |
Insulin Sensitivity Index | Model 2 | MTC | Walford | 2016 | NA | 16753 | 5.00e-2 | 1.95e-2 |
Intracerebral Hemorrhage | All ICH | MTC | Woo | 2014 | 1545 | 1481 | 5.00e-2 | 2.71e-2 |
Intracerebral Hemorrhage | All ICH | MTC | Woo | 2014 | 1545 | 1481 | 1.00e-2 | 4.66e-2 |
Intracerebral Hemorrhage | Nonlobar ICH | MTC | Woo | 2014 | 881 | 1481 | 5.00e-2 | 7.70e-3 |
Ischaemic Stroke | All Stroke | MTC | Traylor | 2012 | 10210 | 12285 | 5.00e-2 | 2.81e-2 |
Ischaemic Stroke | Large Vessel Disease | MTC | Traylor | 2012 | 1877 | 12285 | 5.00e-2 | 3.76e-2 |
Kidney Function | eGFR Decline With Chronic Kidney Disease | MTC | Gorski | 2015 | NA | 45530 | 5.00e-2 | 3.17e-2 |
Longevity | Age 85 Or Greater | MTC | Deelen | 2014 | 7729 | 16121 | 1.00e-3 | 8.45e-3 |
Lymphocyte Subsets | CD56 Level | MTC | Ferreira | 2010 | NA | 2538 | 5.00e-2 | 3.89e-2 |
TBLH BMD | Total body less head bone mineral density | MTC | Medina-Gomez | 2017 | NA | 10414 | 5.00e-2 | 1.33e-2 |
New Onset Diabetes | New Onset Diabetes After Drugs, European American | MTC | Chang | 2018 | 138 | 414 | 1.00e-2 | 2.95e-2 |
Personality Big5 | Extraversion | MTC | De-Moor | 2012 | NA | 17375 | 5.00e-2 | 3.94e-2 |
Personality Big5 | Neuroticism | MTC | De-Moor | 2012 | NA | 17375 | 5.00e-2 | 4.15e-2 |
Pubertal Anthropometrics | Total Pubertal Height Increase | MTC | Cousminer | 2013 | NA | 10799 | 5.00e-2 | 3.21e-2 |
Pubertal Anthropometrics | Total Pubertal Height Increase Females | MTC | Cousminer | 2013 | NA | 10799 | 5.00e-2 | 3.05e-2 |
Pubertal Anthropometrics | Total Pubertal Height Increase Males | MTC | Cousminer | 2013 | NA | 10799 | 5.00e-2 | 4.01e-2 |
Pubertal Anthropometrics | Total Pubertal Height Increase Males | MTC | Cousminer | 2013 | NA | 10799 | 1.00e-2 | 1.53e-2 |
Sleep Duration | Undersleeper | MTC | Jones | 2016 | NA | 110188 | 5.00e-2 | 3.25e-3 |
Sleep Duration | Average Sleep Duration | MTC | Jones | 2016 | NA | 127573 | 1.00e-3 | 3.21e-2 |
Tanner Stage | Tanner Stage All | MTC | Cousminer | 2014 | NA | 9913 | 1.00e-2 | 3.20e-2 |
Type 2 Diabetes | Type 2 Diabetes | MTC | Scott | 2017 | 26676 | 132532 | 5.00e-2 | 6.13e-3 |
Type 2 Diabetes | Type 2 Diabetes | MTC | Scott | 2017 | 26676 | 132532 | 1.00e-3 | 4.12e-2 |
Type 2 Diabetes | Type 2 Diabetes | MTC | Scott | 2017 | 26676 | 132532 | 1.00e-4 | 2.99e-2 |
Type 2 Diabetes | Type 2 Diabetes BMI Adjusted | MTC | Scott | 2017 | 26676 | 132532 | 5.00e-2 | 2.46e-4 |
Type 2 Diabetes | Type 2 Diabetes BMI Adjusted | MTC | Scott | 2017 | 26676 | 132532 | 1.00e-2 | 2.27e-3 |
Type 2 Diabetes | Type 2 Diabetes BMI Adjusted | MTC | Scott | 2017 | 26676 | 132532 | 1.00e-3 | 1.89e-2 |
Waist Format 1 | Waist Hip Ratio Adjusted For BMI European | MTC | Shungin | 2015 | NA | 143480 | 5.00e-2 | 7.00e-3 |
Waist Format 1 | Waist Hip Ratio Adjusted For BMI European | MTC | Shungin | 2015 | NA | 143480 | 1.00e-2 | 1.13e-3 |
Waist Format 1 | Waist Hip Ratio Adjusted For BMI European | MTC | Shungin | 2015 | NA | 143480 | 1.00e-3 | 2.69e-4 |
Waist Format 1 | Waist Hip Ratio Adjusted For BMI European | MTC | Shungin | 2015 | NA | 143480 | 1.00e-4 | 9.20e-3 |
Waist Format 1 | Waist Hip Ratio Adjusted For BMI European | MTC | Shungin | 2015 | NA | 143480 | 1.00e-5 | 1.33e-2 |
Waist Format 1 | Waist Hip Ratio Adjusted For BMI Females European | MTC | Shungin | 2015 | NA | 86570 | 5.00e-2 | 1.05e-2 |
Waist Format 1 | Waist Hip Ratio Adjusted For BMI Females European | MTC | Shungin | 2015 | NA | 86570 | 1.00e-2 | 7.17e-5 |
Waist Format 1 | Waist Hip Ratio Adjusted For BMI Females European | MTC | Shungin | 2015 | NA | 86570 | 1.00e-3 | 1.24e-5 |
Waist Format 1 | Waist Hip Ratio Adjusted For BMI Females European | MTC | Shungin | 2015 | NA | 86570 | 1.00e-4 | 9.71e-3 |
Waist Format 1 | Waist Hip Ratio Adjusted For BMI Males European | MTC | Shungin | 2015 | NA | 56910 | 5.00e-2 | 2.80e-2 |
Waist Format 2 | Hip Circumference Adjusted For BMI European | MTC | Shungin | 2015 | NA | 143480 | 5.00e-2 | 3.68e-2 |
Waist Format 2 | Waist Circumference Adjusted For BMI European | MTC | Shungin | 2015 | NA | 143480 | 5.00e-2 | 1.30e-6 |
Waist Format 2 | Waist Circumference Adjusted For BMI European | MTC | Shungin | 2015 | NA | 143480 | 1.00e-2 | 2.63e-4 |
Waist Format 2 | Waist Circumference Adjusted For BMI European | MTC | Shungin | 2015 | NA | 143480 | 1.00e-3 | 1.18e-2 |
Waist Format 2 | Waist Circumference Adjusted For BMI European | MTC | Shungin | 2015 | NA | 143480 | 1.00e-4 | 9.00e-4 |
Waist Format 2 | Waist Circumference Adjusted For BMI European | MTC | Shungin | 2015 | NA | 143480 | 1.00e-5 | 6.95e-5 |
Waist Format 2 | Waist Circumference Adjusted For BMI Females European | MTC | Shungin | 2015 | NA | 86570 | 5.00e-2 | 8.69e-3 |
Waist Format 2 | Waist Circumference Adjusted For BMI Females European | MTC | Shungin | 2015 | NA | 86570 | 1.00e-2 | 6.61e-3 |
Waist Format 2 | Waist Circumference Adjusted For BMI Females European | MTC | Shungin | 2015 | NA | 86570 | 1.00e-3 | 1.30e-2 |
Waist Format 2 | Waist Circumference Adjusted For BMI Females European | MTC | Shungin | 2015 | NA | 86570 | 1.00e-4 | 2.81e-2 |
Waist Format 2 | Waist Circumference Adjusted For BMI Males European | MTC | Shungin | 2015 | NA | 56910 | 5.00e-2 | 3.71e-5 |
Waist Format 2 | Waist Circumference Adjusted For BMI Males European | MTC | Shungin | 2015 | NA | 56910 | 1.00e-2 | 5.54e-4 |
Waist Format 2 | Waist Circumference Adjusted For BMI Males European | MTC | Shungin | 2015 | NA | 56910 | 1.00e-3 | 2.20e-3 |
Waist Format 2 | Waist Circumference Adjusted For BMI Males European | MTC | Shungin | 2015 | NA | 56910 | 1.00e-4 | 2.01e-4 |
Waist Format 2 | Waist Circumference Adjusted For BMI Males European | MTC | Shungin | 2015 | NA | 56910 | 1.00e-5 | 1.34e-3 |
Waist Format 2 | Waist Hip Ratio European | MTC | Shungin | 2015 | NA | 143480 | 1.00e-2 | 2.52e-2 |
Waist Format 2 | Waist Hip Ratio Females European | MTC | Shungin | 2015 | NA | 86570 | 1.00e-2 | 2.40e-2 |
Waist Format 2 | Waist Hip Ratio Females European | MTC | Shungin | 2015 | NA | 86570 | 1.00e-3 | 4.60e-2 |
PAN | Pancreatic Cancer | ETC | Amundadottir | 2009 | 1771 | 1805 | 5.00e-2 | 3.77e-3 |
HGB | Hemoglobin Concentration | ETC | Astle | 2016 | NA | 173480 | 1.00e-2 | 3.85e-2 |
RHR | CAD Resting Heart Rate | ETC | Eppinga | 2016 | NA | 265046 | 1.00e-2 | 1.29e-3 |
RHR | CAD Resting Heart Rate | ETC | Eppinga | 2016 | NA | 265046 | 1.00e-3 | 8.25e-3 |
RHR | CAD Resting Heart Rate | ETC | Eppinga | 2016 | NA | 265046 | 1.00e-5 | 7.34e-3 |
Parkinsons | Parkinsons disease, age of onset | ETC | Blauwendraat | 2019 | NA | 17996 | 5.00e-2 | 5.98e-3 |
Parkinsons | Parkinsons disease, age of onset | ETC | Blauwendraat | 2019 | NA | 17996 | 1.00e-2 | 1.63e-2 |
Sleep | Sleep efficiency | ETC | Jones | 2019 | NA | 84810 | 5.00e-2 | 2.31e-2 |
Sleep | Sleep duration variability | ETC | Jones | 2019 | NA | 84810 | 5.00e-2 | 6.14e-3 |
Facial attractiveness | Facial attractiveness, male raters | ETC | Hu | 2019 | NA | 3928 | 5.00e-2 | 6.01e-3 |
Facial attractiveness | Facial attractiveness of males, female raters | ETC | Hu | 2019 | NA | 1792 | 5.00e-2 | 2.85e-2 |
Facial attractiveness | Facial attractiveness of females, male raters | ETC | Hu | 2019 | NA | 2062 | 1.00e-2 | 2.70e-2 |
CTS | Carpal tunnel syndrome | ETC | Wiberg | 2019 | 12312 | 389344 | 1.00e-5 | 2.77e-2 |
Obesity | Obesity, extreme obese children vs control adult | ETC | McKay | 2019 | 1456 | 6460 | 5.00e-2 | 3.39e-2 |
Vitiligo | Vitiligo early onset | ETC | Jin | 2019 | 704 | 9031 | 1.00e-4 | 4.03e-2 |
Body fat distribution | Body fat distribution-trunk-fat-ratio-male | ETC | Andersen | 2019 | NA | 116138 | 5.00e-2 | 1.01e-2 |
Osteoarthritis | Osteoarthritis of the hip or knee | ETC | Tachmazidou | 2019 | 39427 | 378169 | 5.00e-2 | 2.15e-2 |
Osteoarthritis | Knee osteoarthritis | ETC | Tachmazidou | 2019 | 24955 | 376169 | 1.00e-2 | 3.02e-2 |
Brain volume | White matter hyperintensity volume | ETC | Traylor | 2019 | NA | 8429 | 5.00e-2 | 2.18e-2 |
Brain volume | White matter hyperintensity volume | ETC | Traylor | 2019 | NA | 8429 | 1.00e-4 | 2.58e-2 |
Hippocampal volume | Hippocampal subfield CA1 volume | ETC | Meer | 2018 | NA | 21297 | 1.00e-3 | 4.89e-2 |
Hippocampal volume | Hippocampal tail volume, corrected for total hippocampal volume | ETC | Meer | 2018 | NA | 21297 | 1.00e-2 | 2.82e-2 |
Hippocampal volume | Hippocampal fissure volume, corrected for total hippocampal volume | ETC | Meer | 2018 | NA | 21297 | 5.00e-2 | 2.84e-2 |
IHPS | Infantile hypertrophic pyloric stenosis | ETC | Fadista | 2018 | NA | 4438 | 5.00e-2 | 1.66e-4 |
IHPS | Infantile hypertrophic pyloric stenosis | ETC | Fadista | 2018 | NA | 4438 | 1.00e-2 | 1.30e-5 |
AUDIT-C | Alcohol-Use-Disorder-Identification-Test-Consumption | ETC | Kranzler | 2019 | NA | 200680 | 5.00e-2 | 4.97e-2 |
Medication use | Medication use (vasodilators used in cardiac diseases) | ETC | Wu Y | 2019 | 5,546 | 237,113 | 5.00e-2 | 3.05e-2 |
Medication use | Medication use (drugs affecting bone structure and mineralization) | ETC | Wu Y | 2019 | 7,870 | 207,798 | 5.00e-2 | 9.10e-3 |
Medication use | Medication use (drugs affecting bone structure and mineralization) | ETC | Wu Y | 2019 | 7,870 | 207,798 | 1.00e-2 | 4.81e-2 |
Medication use | Medication use (antihistamines for systemic use) | ETC | Wu Y | 2019 | 13,984 | 137,652 | 1.00e-3 | 3.11e-2 |
Medication use | Medication use (antihistamines for systemic use) | ETC | Wu Y | 2019 | 13,984 | 137,652 | 1.00e-4 | 3.44e-2 |
Medication use | Medication use (antiglaucoma preparations and miotics) | ETC | Wu Y | 2019 | 5,215 | 95,653 | 5.00e-2 | 3.14e-2 |
Medication use | Medication use (antiglaucoma preparations and miotics) | ETC | Wu Y | 2019 | 5,215 | 95,653 | 1.00e-3 | 3.56e-2 |
Diverticular disease | Diverticular disease | ETC | Schafmayer C | 2019 | 31,964 | 419,135 | 5.00e-2 | 3.68e-3 |
Diverticular disease | Diverticular disease | ETC | Schafmayer C | 2019 | 31,964 | 419,135 | 1.00e-2 | 2.57e-3 |
Diverticular disease | Diverticular disease | ETC | Schafmayer C | 2019 | 31,964 | 419,135 | 1.00e-3 | 1.10e-5 |
Diverticular disease | Diverticular disease | ETC | Schafmayer C | 2019 | 31,964 | 419,135 | 1.00e-4 | 2.54e-4 |
Diverticular disease | Diverticular disease | ETC | Schafmayer C | 2019 | 31,964 | 419,135 | 1.00e-5 | 3.50e-2 |
same-sex sexual behaviour | same-sex sexual behaviour | ETC | Ganna A | 2019 | NA | 408,995 | 5.00e-2 | 2.78e-2 |
Knee pain | Knee pain | ETC | Meng W | 2019 | 22,204 | 149,312 | 1.00e-2 | 2.08e-2 |
Parietal lobe volume | Parietal lobe volume | ETC | van der Lee SJ | 2019 | NA | 15,269 | 5.00e-2 | 3.07e-2 |
Visceral adipose tissue | Predicted visceral adipose tissue Male | ETC | Karlsson T | 2019 | NA | 163,984 | 1.00e-2 | 4.65e-2 |
Birth | Gestational age at birth (child effect) | ETC | Liu X | 2019 | NA | 84,689 | 1.00e-2 | 1.66e-2 |
Asthma | Asthma (childhood onset) | ETC | Zhu Z | 2019 | 9,676 | 347,481 | 1.00e-4 | 4.45e-2 |
Asthma | Asthma (childhood onset) | ETC | Zhu Z | 2019 | 9,676 | 347,481 | 1.00e-5 | 1.65e-2 |
Waist to hip ratio | Waist-to-hip ratio adjusted for BMI | ETC | Pulit SL | 2019 | NA | 379,501 | 1.00e-3 | 3.41e-4 |
Waist to hip ratio | Waist-to-hip ratio adjusted for BMI | ETC | Pulit SL | 2019 | NA | 379,501 | 1.00e-4 | 5.04e-4 |
Waist to hip ratio | Waist-to-hip ratio adjusted for BMI | ETC | Pulit SL | 2019 | NA | 379,501 | 1.00e-5 | 6.35e-5 |
Waist to hip ratio | Waist-to-hip ratio adjusted for BMI | ETC | Pulit SL | 2019 | NA | 315,284 | 1.00e-2 | 1.22e-2 |
Waist to hip ratio | Waist-to-hip ratio adjusted for BMI | ETC | Pulit SL | 2019 | NA | 315,284 | 1.00e-4 | 1.20e-2 |
Waist to hip ratio | Waist-to-hip ratio adjusted for BMI | ETC | Pulit SL | 2019 | NA | 315,284 | 1.00e-5 | 7.26e-3 |
Waist to hip ratio | Waist-hip ratio | ETC | Pulit SL | 2019 | NA | 697,734 | 1.00e-4 | 1.08e-4 |
Waist to hip ratio | Waist-hip ratio | ETC | Pulit SL | 2019 | NA | 697,734 | 1.00e-5 | 2.45e-3 |
Waist to hip ratio | Waist-hip ratio | ETC | Pulit SL | 2019 | NA | 381,152 | 1.00e-3 | 1.99e-3 |
Waist to hip ratio | Waist-hip ratio | ETC | Pulit SL | 2019 | NA | 381,152 | 1.00e-4 | 6.64e-3 |
Waist to hip ratio | Waist-to-hip ratio adjusted for BMI | ETC | Pulit SL | 2019 | NA | 694,649 | 1.00e-4 | 6.86e-5 |
Waist to hip ratio | Waist-to-hip ratio adjusted for BMI | ETC | Pulit SL | 2019 | NA | 694,649 | 1.00e-5 | 3.90e-5 |
Joint damage | Joint damage in rheumatoid arthritis | ETC | Traylor M | 2019 | NA | 2,527 | 1.00e-2 | 2.57e-2 |
Body fat percentage | Body fat percentage variance | ETC | Wang H | 2019 | NA | 341,632 | 5.00e-2 | 3.21e-2 |
Heel bone mineral Density | Heel bone mineral density variance | ETC | Wang H | 2019 | NA | 197,261 | 1.00e-3 | 1.40e-2 |
Cytokine network | Cytokine network levels (multivariate analysis) | ETC | Nath AP | 2019 | NA | 9,263 | 1.00e-2 | 2.40e-2 |
Cytokine network | Cytokine network levels (multivariate analysis) | ETC | Nath AP | 2019 | NA | 9,263 | 1.00e-3 | 2.14e-2 |
Eosinophilic granulomatosis | Eosinophilic granulomatosis with polyangiitis (MPO-ANCA positive) | ETC | Lyons PA | 2019 | 159 | 6,688 | 1.00e-3 | 1.42e-2 |
BMI by age | BMI at 6 weeks old | ETC | Helgeland O | 2019 | NA | 6,450 | 1.00e-2 | 3.74e-2 |
BMI by age | BMI at 2 years old | ETC | Helgeland O | 2019 | NA | 4,631 | 1.00e-3 | 1.43e-2 |
BMI by age | BMI at 8 years old | ETC | Helgeland O | 2019 | NA | 3,862 | 5.00e-2 | 3.40e-2 |
PD | Parkinson's disease in GBA mutation carriers | ETC | Blauwendraat C | 2020 | 1,588 | 7,584 | 5.00e-2 | 3.06e-2 |
Left ventricular | Left ventricular end-systolic volume | ETC | Aung N | 2019 | NA | 16,920 | 1.00e-2 | 2.14e-2 |
Left ventricular | Left ventricular end-systolic volume | ETC | Aung N | 2019 | NA | 16,920 | 1.00e-4 | 6.52e-3 |
Left ventricular | Left ventricular end-systolic volume | ETC | Aung N | 2019 | NA | 16,920 | 1.00e-5 | 2.97e-2 |
Left ventricular | Left ventricular ejection fraction | ETC | Aung N | 2019 | NA | 16,923 | 1.00e-2 | 2.23e-2 |
Left ventricular | Left ventricular ejection fraction | ETC | Aung N | 2019 | NA | 16,923 | 1.00e-3 | 2.02e-2 |
Left ventricular | Left ventricular mass | ETC | Aung N | 2019 | NA | 16,920 | 1.00e-4 | 2.21e-2 |
Left ventricular | Left ventricular end-diastolic volume | ETC | Aung N | 2019 | NA | 16,920 | 1.00e-3 | 6.40e-3 |
Left ventricular | Left ventricular end-diastolic volume | ETC | Aung N | 2019 | NA | 16,920 | 1.00e-4 | 6.37e-3 |
Left ventricular | Left ventricular end-diastolic volume | ETC | Aung N | 2019 | NA | 16,920 | 1.00e-5 | 1.58e-2 |
Optic cup area | Optic cup area | ETC | Bonnemaijer PWM | 2019 | NA | 24,493 | 5.00e-2 | 2.47e-5 |
Optic cup area | Optic cup area | ETC | Bonnemaijer PWM | 2019 | NA | 24,493 | 1.00e-2 | 2.18e-4 |
Optic cup area | Optic cup area | ETC | Bonnemaijer PWM | 2019 | NA | 24,493 | 1.00e-3 | 7.51e-3 |
Optic disc area | Optic disc area | ETC | Bonnemaijer PWM | 2019 | NA | 24,509 | 5.00e-2 | 5.53e-4 |
Optic disc area | Optic disc area | ETC | Bonnemaijer PWM | 2019 | NA | 24,509 | 1.00e-2 | 2.74e-4 |
Vertical cup to disc ratio | Vertical cup-disc ratio | ETC | Bonnemaijer PWM | 2019 | NA | 25,180 | 5.00e-2 | 8.10e-6 |
Vertical cup to disc ratio | Vertical cup-disc ratio | ETC | Bonnemaijer PWM | 2019 | NA | 25,180 | 1.00e-2 | 5.09e-3 |
Vertical cup to disc ratio | Vertical cup-disc ratio | ETC | Bonnemaijer PWM | 2019 | NA | 25,180 | 1.00e-3 | 4.24e-3 |
Intraocular pressure | Intraocular pressure | ETC | Bonnemaijer PWM | 2019 | NA | 31,269 | 1.00e-2 | 5.21e-3 |
Intraocular pressure | Intraocular pressure | ETC | Bonnemaijer PWM | 2019 | NA | 31,269 | 1.00e-4 | 2.02e-2 |
Intraocular pressure | Intraocular pressure | ETC | Bonnemaijer PWM | 2019 | NA | 31,269 | 1.00e-5 | 9.35e-3 |
Central corneal thickness | Central corneal thickness | ETC | Bonnemaijer PWM | 2019 | NA | 16,204 | 1.00e-3 | 1.94e-2 |
Central corneal thickness | Central corneal thickness | ETC | Bonnemaijer PWM | 2019 | NA | 16,204 | 1.00e-4 | 9.00e-3 |
Central corneal thickness | Central corneal thickness | ETC | Bonnemaijer PWM | 2019 | NA | 16,204 | 1.00e-5 | 2.13e-2 |
Refractive error | Refractive error (age-at-onset of spectacle wearing-inferred) | ETC | Ghorbani Mojarrad N | 2020 | NA | 287,448 | 1.00e-2 | 1.20e-2 |
Refractive error | Refractive error (age-at-onset of spectacle wearing-inferred) | ETC | Ghorbani Mojarrad N | 2020 | NA | 287,448 | 1.00e-3 | 6.17e-3 |
Refractive error | Refractive error (age-at-onset of spectacle wearing-inferred) | ETC | Ghorbani Mojarrad N | 2020 | NA | 287,448 | 1.00e-4 | 2.64e-3 |
Refractive error | Refractive error (age-at-onset of spectacle wearing-inferred) | ETC | Ghorbani Mojarrad N | 2020 | NA | 287,448 | 1.00e-5 | 1.63e-4 |
Refractive error | Refractive error (autorefraction measured) | ETC | Ghorbani Mojarrad N | 2020 | NA | 95,619 | 1.00e-2 | 3.08e-3 |
Refractive error | Refractive error (autorefraction measured) | ETC | Ghorbani Mojarrad N | 2020 | NA | 95,619 | 1.00e-3 | 2.01e-2 |
Refractive error | Refractive error (autorefraction measured) | ETC | Ghorbani Mojarrad N | 2020 | NA | 95,619 | 1.00e-4 | 9.24e-3 |
Refractive error | Refractive error (autorefraction measured) | ETC | Ghorbani Mojarrad N | 2020 | NA | 95,619 | 1.00e-5 | 4.46e-2 |
CCL19 | CCL19 levels | ETC | Enroth S | 2014 | NA | 653 | 1.00e-3 | 4.60e-2 |
CCL19 | CCL19 levels | ETC | Enroth S | 2014 | NA | 653 | 1.00e-4 | 3.41e-2 |
CCL19 | CCL19 levels | ETC | Enroth S | 2014 | NA | 653 | 1.00e-5 | 1.58e-2 |
IL 6 | Interleukin-6 receptor subunit alpha levels | ETC | Enroth S | 2014 | NA | 653 | 1.00e-2 | 2.86e-2 |
IL 6 | Interleukin-6 receptor subunit alpha levels | ETC | Enroth S | 2014 | NA | 653 | 1.00e-4 | 2.84e-2 |
IL 6 | Interleukin-6 receptor subunit alpha levels | ETC | Enroth S | 2014 | NA | 653 | 1.00e-5 | 4.40e-2 |
C-X-C chmokine | C-X-C motif chemokine 10 levels | ETC | Enroth S | 2014 | NA | 653 | 1.00e-2 | 3.78e-3 |
C-X-C chmokine | C-X-C motif chemokine 10 levels | ETC | Enroth S | 2014 | NA | 653 | 1.00e-3 | 8.66e-3 |
C-X-C chmokine | C-X-C motif chemokine 10 levels | ETC | Enroth S | 2014 | NA | 653 | 1.00e-4 | 3.23e-2 |
C-X-C chmokine | C-X-C motif chemokine 10 levels | ETC | Enroth S | 2014 | NA | 653 | 1.00e-5 | 1.38e-2 |
CCL24 | CCL24 levels | ETC | Enroth S | 2014 | NA | 653 | 1.00e-4 | 1.97e-2 |
CCL24 | CCL24 levels | ETC | Enroth S | 2014 | NA | 653 | 1.00e-5 | 2.58e-2 |
MHC class I | MHC class I polypeptide-related sequence A levels | ETC | Enroth S | 2014 | NA | 653 | 1.00e-5 | 3.99e-2 |
CD40 | CD40 ligand levels | ETC | Enroth S | 2014 | NA | 653 | 5.00e-2 | 2.28e-3 |
CD40 | CD40 ligand levels | ETC | Enroth S | 2014 | NA | 653 | 1.00e-2 | 6.87e-4 |
CD40 | CD40 ligand levels | ETC | Enroth S | 2014 | NA | 653 | 1.00e-3 | 4.80e-2 |
CD40 | CD40 ligand levels | ETC | Enroth S | 2014 | NA | 653 | 1.00e-4 | 5.36e-3 |
CD40 | CD40 ligand levels | ETC | Enroth S | 2014 | NA | 653 | 1.00e-5 | 3.41e-2 |
CXCL5 | CXCL5 levels | ETC | Enroth S | 2014 | NA | 653 | 5.00e-2 | 1.81e-4 |
CXCL5 | CXCL5 levels | ETC | Enroth S | 2014 | NA | 653 | 1.00e-2 | 2.50e-4 |
CXCL5 | CXCL5 levels | ETC | Enroth S | 2014 | NA | 653 | 1.00e-3 | 4.43e-3 |
CXCL5 | CXCL5 levels | ETC | Enroth S | 2014 | NA | 653 | 1.00e-4 | 2.66e-2 |
CXCL5 | CXCL5 levels | ETC | Enroth S | 2014 | NA | 653 | 1.00e-5 | 2.03e-2 |
Kallikrein11 | kallikrein-11 levels | ETC | Enroth S | 2014 | NA | 653 | 1.00e-3 | 4.98e-2 |
Kallikrein11 | kallikrein-11 levels | ETC | Enroth S | 2014 | NA | 653 | 1.00e-4 | 3.98e-2 |
Kallikrein11 | kallikrein-11 levels | ETC | Enroth S | 2014 | NA | 653 | 1.00e-5 | 1.48e-2 |
Epithelial | epithelial cell adhesion molecule levels | ETC | Enroth S | 2014 | NA | 653 | 1.00e-4 | 2.02e-2 |
Epithelial | epithelial cell adhesion molecule levels | ETC | Enroth S | 2014 | NA | 653 | 1.00e-5 | 7.12e-3 |
IL 17 | interleukin 17 receptor B levels | ETC | Enroth S | 2014 | NA | 653 | 1.00e-4 | 3.78e-2 |
IL 17 | interleukin 17 receptor B levels | ETC | Enroth S | 2014 | NA | 653 | 1.00e-5 | 1.20e-2 |
IL 12 | interleukin 12 receptor subunit beta-1 levels | ETC | Enroth S | 2014 | NA | 653 | 1.00e-3 | 3.77e-2 |
IL 12 | interleukin 12 receptor subunit beta-1 levels | ETC | Enroth S | 2014 | NA | 653 | 1.00e-4 | 1.41e-2 |
IL 12 | interleukin 12 receptor subunit beta-1 levels | ETC | Enroth S | 2014 | NA | 653 | 1.00e-5 | 1.12e-2 |
Endothelial | vascular endothelial growth factor D levels | ETC | Enroth S | 2014 | NA | 653 | 5.00e-2 | 5.16e-5 |
Endothelial | vascular endothelial growth factor D levels | ETC | Enroth S | 2014 | NA | 653 | 1.00e-2 | 4.81e-2 |
Endothelial | vascular endothelial growth factor D levels | ETC | Enroth S | 2014 | NA | 653 | 1.00e-3 | 4.64e-2 |
Endothelial | vascular endothelial growth factor D levels | ETC | Enroth S | 2014 | NA | 653 | 1.00e-5 | 2.16e-2 |
E-selectin | E-selectin levels | ETC | Enroth S | 2014 | NA | 653 | 1.00e-4 | 1.90e-2 |
E-selectin | E-selectin levels | ETC | Enroth S | 2014 | NA | 653 | 1.00e-5 | 1.12e-2 |
Melanoma | melanoma-derived growth regulatory protein levels | ETC | Enroth S | 2014 | NA | 653 | 1.00e-4 | 2.81e-2 |
Melanoma | melanoma-derived growth regulatory protein levels | ETC | Enroth S | 2014 | NA | 653 | 1.00e-5 | 1.58e-2 |
Glaucoma (MTAG) | Glaucoma (multi-trait analysis) | ETC | Craig JE | 2020 | 119,318 | 232,378 | 5.00e-2 | 1.08e-3 |
Glaucoma (MTAG) | Glaucoma (multi-trait analysis) | ETC | Craig JE | 2020 | 119,318 | 232,378 | 1.00e-2 | 1.70e-5 |
Glaucoma (MTAG) | Glaucoma (multi-trait analysis) | ETC | Craig JE | 2020 | 119,318 | 232,378 | 1.00e-3 | 2.37e-5 |
Glaucoma (MTAG) | Glaucoma (multi-trait analysis) | ETC | Craig JE | 2020 | 119,318 | 232,378 | 1.00e-4 | 1.84e-6 |
Glaucoma (MTAG) | Glaucoma (multi-trait analysis) | ETC | Craig JE | 2020 | 119,318 | 232,378 | 1.00e-5 | 4.90e-6 |
Retinal detachment | Retinal detachment or retinal break | ETC | Boutin TS | 2020 | 6148 | 59546 | 1.00e-3 | 2.90e-3 |
Retinal detachment | Retinal detachment or retinal break | ETC | Boutin TS | 2020 | 6148 | 59546 | 1.00e-4 | 9.44e-3 |
Alzheimer's disease (late onset) | late-onset Alzheimers disease | ETC | Kunkle BW | 2019 | 21982 | 41944 | 1.00e-5 | 4.02e-3 |
* If the number of cases is 0/NA, it means the phenotype is a continuous data type and the number of controls is the total number of samples.